Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal-Reference-Cited by-同舟云学术

Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal

Published:2016-10-11 Issue:2 Volume:86 Page:207-213
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Watanabe Shinya¹,Akutsu Hiroyoshi¹,Takano Shingo¹,Yamamoto Tetsuya¹,Ishikawa Eiichi¹,Suzuki Hiroaki²,Matsumura Akira¹

Affiliation:

1. Department of Neurosurgery; Faculty of Medicine; University of Tsukuba; Tsukuba Ibaraki Japan

2. Division of Endocrinology and Metabolism; Department of Internal Medicine; Faculty of Medicine; University of Tsukuba; Tsukuba Ibaraki Japan

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cen.13240/fullpdf

Reference21 articles.

1. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group;Webster;New England Journal of Medicine,1994

2. Treatment of macroprolactinoma with cabergoline: a study of 85 patients;Ferrari;Clinical Endocrinology,1997

3. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients;Verhelst;Journal of Clinical Endocrinology and Metabolism,1999

4. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients;Colao;Journal of Clinical Endocrinology and Metabolism,2000

5. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group;Webster;Clinical Endocrinology,1992

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Maternal Thyroid Dysfunction on Fetal and Maternal Outcomes in Pregnancy: A Prospective Cohort Study;2024-01-31

2. Withdrawal of dopamine agonist treatment in patients with hyperprolactinaemia: A systematic review and meta‐analysis;Clinical Endocrinology;2022-03-22

3. Prolactinoma;The Pituitary;2022

4. The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis;BMC Endocrine Disorders;2021-11-13

5. Hyperprolactinemia in the postmenopause: versions and contraversions;Terapevticheskii arkhiv;2021-10-15